A team led by investigators from Massachusetts General Hospital (MGH), Brigham and Women's Hospital (BWH) and the Broad Institute has found that a gene mutation associated with several types of cancer also may be responsible ...
Jan 12, 2014
0
0
Stand Up To Cancer (SU2C), the charitable initiative supporting ground-breaking research aimed at getting new cancer treatments to patients in an accelerated timeframe, announces that Jeffrey A. Sosman, M.D., a Stand Up To ...
Dec 31, 2013
0
0
(HealthDay)—Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas (NPMs), although the incidence rates are lower than those observed ...
Dec 10, 2013
0
0
Genomic profiling of treatment-resistant, BRAF-mutated melanomas revealed multiple gene alterations, mostly involving a cell-signaling pathway called the MAPK pathway, and more potent forms of existing drugs and drugs targeting ...
Nov 22, 2013
0
0
Stand Up To Cancer (SU2C), the charitable initiative supporting ground-breaking research aimed at getting new cancer treatments to patients in an accelerated timeframe, announces that the Allan H. (Bud) and Sue Selig Stand ...
Nov 21, 2013
0
0
Melanoma is the deadliest form of skin cancer, killing more than 8,000 in the U.S. each year. Approximately 40 percent of advanced melanoma tumors are driven to grow by the presence of mutations in a gene known as the BRAF ...
Nov 21, 2013
0
0
Research led by Broad senior associate member Levi Garraway and published this week in Nature offers a new approach to studying drug resistance in cancer. The approach helped them identify which biological pathways could ...
Nov 11, 2013
0
0
A functional biomarker that can predict whether BRAF-mutant melanomas respond to drugs targeting BRAF could help guide the treatment of patients with these cancers, according to results presented here at the AACR-NCI-EORTC ...
Oct 22, 2013
0
0
A new diagnostic platform to detect BRAF mutations in melanoma and other cancer types is faster and more accurate compared with the standard method currently used in clinics, and this could help accelerate diagnosis and treatment, ...
Oct 22, 2013
0
0
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination ...
Oct 20, 2013
0
0
